Avinger (NASDAQ:AVGR – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Earnings & Valuation
This table compares Avinger and ClearPoint Neuro”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avinger | $7.26 million | 0.22 | -$18.32 million | ($11.06) | -0.04 |
| ClearPoint Neuro | $31.39 million | 9.36 | -$22.09 million | ($0.70) | -15.19 |
Avinger has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avinger | 0 | 0 | 0 | 0 | 0.00 |
| ClearPoint Neuro | 0 | 0 | 3 | 0 | 3.00 |
ClearPoint Neuro has a consensus price target of $25.00, suggesting a potential upside of 135.18%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Avinger.
Risk & Volatility
Avinger has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
Insider & Institutional Ownership
18.3% of Avinger shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 42.8% of Avinger shares are held by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Avinger and ClearPoint Neuro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avinger | -261.06% | -5,527.11% | -123.25% |
| ClearPoint Neuro | -59.64% | -62.10% | -38.39% |
Summary
ClearPoint Neuro beats Avinger on 10 of the 14 factors compared between the two stocks.
About Avinger
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.
